Transgene S.A.
TRGNF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6,353 | $7,900 | $3,126 | $9,993 |
| % Growth | -19.6% | 152.7% | -68.7% | – |
| Cost of Goods Sold | $34,278 | $29,588 | $32,168 | $32,883 |
| Gross Profit | -$27,925 | -$21,688 | -$29,042 | -$22,890 |
| % Margin | -439.6% | -274.5% | -929% | -229.1% |
| R&D Expenses | $34,278 | $29,588 | $32,168 | $32,883 |
| G&A Expenses | $4 | $6,987 | $3,221 | $2,594 |
| SG&A Expenses | $4 | $3,818 | $3,221 | $2,594 |
| Sales & Mktg Exp. | $0 | -$3,169 | $0 | $0 |
| Other Operating Expenses | -$26,549 | -$25,047 | -$2,136 | -$1,738 |
| Operating Expenses | $7,733 | $8,359 | $33,253 | $33,739 |
| Operating Income | -$35,658 | -$30,047 | -$29,904 | -$23,525 |
| % Margin | -561.3% | -380.3% | -956.6% | -235.4% |
| Other Income/Exp. Net | $1,687 | $7,719 | -$2,900 | $4,159 |
| Pre-Tax Income | -$33,971 | -$22,328 | -$32,804 | -$19,536 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$33,971 | -$22,328 | -$32,810 | -$20,004 |
| % Margin | -534.7% | -282.6% | -1,049.6% | -200.2% |
| EPS | -0.34 | -0.22 | -0.33 | -0.22 |
| % Growth | -54.5% | 33.3% | -50% | – |
| EPS Diluted | -0.34 | -0.22 | -0.33 | -0.22 |
| Weighted Avg Shares Out | 100,957 | 101,491 | 99,502 | 91,112 |
| Weighted Avg Shares Out Dil | 100,957 | 100,590 | 99,502 | 91,112 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $7,338 | $309 | $4,198 |
| Interest Expense | $1,681 | $0 | $804 | $464 |
| Depreciation & Amortization | $1,281 | $1,572 | $1,673 | $2,509 |
| EBITDA | -$26,652 | -$28,440 | -$30,327 | -$23,550 |
| % Margin | -419.5% | -360% | -970.2% | -235.7% |